Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND),Blood Cancer Journal

当前位置： X-MOL 学术 › Blood Cancer J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2024-02-20 , DOI: 10.1038/s41408-024-01000-2
Talha Badar , Ahmad Nanaa , Ehab Atallah , Rory M. Shallis , Sacchi de Camargo Correia Guilherme , Aaron D. Goldberg , Antoine N. Saliba , Anand Patel , Jan P. Bewersdorf , Adam S. DuVall , Danielle Bradshaw , Yasmin Abaza , Guru Subramanian Guru Murthy , Neil Palmisiano , Amer M. Zeidan , Vamsi Kota , Mark R. Litzow